University Of Alabama Hospital
- Type
- Teaching hospital
- Where
- BIRMINGHAM, AL
- Medicare CCN
- 010033
- Received
- $42,200,244 in 3,565 records, 2020 ($2,613,751 general, $39,586,492 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: UNIVERSITY OF ALABAMA HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 323 | $2,613,751 |
| 2020 | Research payment | 3,242 | $39,586,492 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3,242 | $39,586,492 |
| Grant | 52 | $1,396,259 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 80 | $428,162 |
| Education | 71 | $346,828 |
| Consulting Fee | 8 | $240,797 |
| Space rental or facility fees (teaching hospital only) | 94 | $91,543 |
| Royalty or License | 3 | $91,330 |
| Gift | 13 | $18,404 |
| Charitable Contribution | 1 | $375 |
| Food and Beverage | 1 | $51 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Gilead Sciences, Inc. | $465,965 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $15,363 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $13,080 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | AngioDynamics, Inc. | $13,000 | Education | In-kind items and services | Solero Device, Oncology Surgery | 2020 | |
| 2020-12-31 | AngioDynamics, Inc. | $13,000 | Education | In-kind items and services | Solero Device, Oncology Surgery | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $12,518 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $10,319 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with | 2020 |
| 2020-12-31 | AstraZeneca UK Limited | $8,843 | Research payment | In-kind items and services | The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre R | 2020 | |
| 2020-12-31 | Allergan, Inc. | $7,519 | Research payment | In-kind items and services | A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group | 2020 | |
| 2020-12-31 | AngioDynamics, Inc. | $6,969 | Education | In-kind items and services | Solero Device, Oncology Surgery | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $5,038 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2020 |
| 2020-12-31 | Roche Diagnostics Corporation | $3,333 | Education | In-kind items and services | DIS Navify Software Device, Diagnostic Information Solutions | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,680 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,500 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Allergan, Inc. | $2,086 | Research payment | In-kind items and services | A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Ph | 2020 | |
| 2020-12-31 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $925 | Education | In-kind items and services | C-MAC VIDEO LARYNGOSCOPE MAC #3 Device, H-ANESTHESIOLOGY | 2020 | |
| 2020-12-31 | Allergan, Inc. | $900 | Research payment | In-kind items and services | A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamoreli | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $750 | Research payment | Cash or cash equivalent | UAlabama2019MRIPR1058IPR1084Kim | 2020 | |
| 2020-12-31 | Edwards Lifesciences Corporation | $280 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2020 | |
| 2020-12-31 | Edwards Lifesciences Corporation | $184 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2020 | |
| 2020-12-31 | Abbott Laboratories | $105 | Research payment | In-kind items and services | MitraClip Device, Vascular | Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Ca | 2020 |
| 2020-12-31 | Tulsa Dental Products LLC | $96 | Education | In-kind items and services | Endodontic Dentistry Device, Endodontic Dentistry | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $10 | Research payment | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic | 2020 |
| 2020-12-31 | AstraZeneca UK Limited | $4 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have | 2020 |
| 2020-12-30 | ABBVIE INC. | $15,024 | Research payment | Cash or cash equivalent | M17-327 | 2020 | |
| 2020-12-30 | ABBVIE INC. | $11,993 | Research payment | Cash or cash equivalent | M15-741 | 2020 | |
| 2020-12-30 | ABBVIE INC. | $6,077 | Research payment | Cash or cash equivalent | M16-109 | 2020 | |
| 2020-12-30 | ABBVIE INC. | $5,028 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-538 | 2020 |
| 2020-12-30 | ABBVIE INC. | $3,210 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M15-997 | 2020 |
| 2020-12-30 | ABBVIE INC. | $2,210 | Research payment | Cash or cash equivalent | M17-327 | 2020 | |
| 2020-12-30 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2020 |
| 2020-12-30 | ABBVIE INC. | $169 | Research payment | Cash or cash equivalent | M16-109 | 2020 | |
| 2020-12-30 | KARL STORZ Endoscopy-America | $146 | Education | In-kind items and services | C-MAC CONNECTION CABLE Device, H-ANESTHESIOLOGY | 2020 | |
| 2020-12-29 | United Therapeutics Corporation | $17,649 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | 2020 |
| 2020-12-29 | United Therapeutics Corporation | $3,393 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2020 |
| 2020-12-29 | Otsuka Pharmaceutical Co., Ltd. | $1,859 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE (ASTX727 LD) EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK | 2020 | |
| 2020-12-29 | Otsuka Pharmaceutical Co., Ltd. | $538 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE (ASTX727 LD) EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK | 2020 | |
| 2020-12-28 | Amgen Inc. | $40,801 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis(PSOR-025) | 2020 |
| 2020-12-28 | Ormco Corporation | $34,341 | Education | In-kind items and services | NOT RELATED TO ANY PRODUCT Device, NOT APPLICABLE | 2020 | |
| 2020-12-24 | PFIZER INC. | $1,204 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2020 | |
| 2020-12-24 | GENZYME CORPORATION | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | THYMOGLOBULIN Biological, Oncology | 2020 | |
| 2020-12-24 | PFIZER INC. | $563 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2020 | |
| 2020-12-24 | Amgen Inc. | $302 | Research payment | Cash or cash equivalent | IMLYGIC Biological, Oncology | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-12-24 | Amgen Inc. | $142 | Research payment | Cash or cash equivalent | IMLYGIC Biological, Oncology | P2 Neo-adjuvant melanoma | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $32,438 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2020 |
| 2020-12-23 | SEAGEN INC. | $29,610 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2020 | |
| 2020-12-23 | Corcept Therapeutics | $29,300 | Research payment | Cash or cash equivalent | CORT125134-552 | 2020 | |
| 2020-12-23 | SEAGEN INC. | $28,531 | Research payment | Cash or cash equivalent | A Study of SGN-CD228A in Advanced Solid Tumors | 2020 | |
| 2020-12-23 | Novocure Inc. | $22,773 | Research payment | Cash or cash equivalent | Optune Device, Oncology | A Pilot and Feasibility Trial to Determine the Rate of the Brain Relapse in Small Cell Lung Canser (SCLC) Patients with | 2020 |
| 2020-12-23 | SEAGEN INC. | $13,700 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2020 | |
| 2020-12-23 | SEAGEN INC. | $8,340 | Research payment | Cash or cash equivalent | A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $6,433 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-12-23 | PFIZER INC. | $5,445 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2020 | |
| 2020-12-23 | SEAGEN INC. | $481 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2020 | |
| 2020-12-23 | Novo Nordisk AS | $429 | Research payment | In-kind items and services | Wegovy Drug, Diabetes | NN9536-4576 | 2020 |
| 2020-12-23 | SEAGEN INC. | $189 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2020 |
| 2020-12-23 | Novo Nordisk AS | $128 | Research payment | In-kind items and services | Wegovy Drug, Diabetes | NN9536-4576 | 2020 |
| 2020-12-22 | Takeda Pharmaceuticals U.S.A., Inc. | $116,537 | Research payment | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | INNOVATIVE TRIAL FOR UNDERSTANDING THE IMPACT OF TARGETED THERAPIES IN NF2 (INTUITT-NF2) | 2020 |
| 2020-12-22 | ABBVIE INC. | $24,700 | Research payment | Cash or cash equivalent | M15-737 | 2020 | |
| 2020-12-22 | Stryker Corporation | $15,150 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | A RETROSPECTIVE DATA COLLECTION OF THE TREATMENT OF TIBIA FRACTURES WITH THE T2 ALPHA TIBIA NAILING SYSTEM | 2020 |
| 2020-12-22 | Incyte Corporation | $13,826 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $13,826 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $10,522 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $10,351 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $9,325 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Stryker Corporation | $7,100 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | A?RETROSPECTIVE DATA COLLECTION?OF THE TREATMENT OF FEMORAL FRACTURES WITH THE?FEMORAL NAIL GREATER TROCHANTER (GT) OF T | 2020 |
| 2020-12-22 | Incyte Corporation | $7,037 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $6,913 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $5,647 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $5,589 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | F. Hoffmann-La Roche AG | $5,580 | Research payment | Cash or cash equivalent | GAZYVA Biological, BioOncology | G APDL1 LENALIDOMIDE IN R R FL | 2020 |
| 2020-12-22 | Ethicon Inc. | $4,106 | Research payment | Cash or cash equivalent | EVARREST Biological, Biosurgical | A Prospective Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Sealant Patch in Controlling Mild or Mode | 2020 |
| 2020-12-22 | Incyte Corporation | $3,957 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $2,210 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | JAZZ PHARMACEUTICALS INC. | $2,148 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2020 |
| 2020-12-22 | Incyte Corporation | $2,126 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $2,123 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $1,248 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $1,040 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $1,024 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | F. Hoffmann-La Roche AG | $750 | Research payment | Cash or cash equivalent | GAZYVA Biological, BioOncology | G APDL1 LENALIDOMIDE IN R R FL | 2020 |
| 2020-12-22 | Incyte Corporation | $650 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $650 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $650 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $586 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $439 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $338 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $325 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | F. Hoffmann-La Roche AG | $289 | Research payment | Cash or cash equivalent | GAZYVA Biological, BioOncology | G APDL1 LENALIDOMIDE IN R R FL | 2020 |
| 2020-12-22 | Incyte Corporation | $262 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $248 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $169 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $124 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-21 | Amgen Inc. | $676,071 | Research payment | Cash or cash equivalent | EVENITY Biological, Bone Health | Clinical Characteristics, including History of MI and Stroke, among US Post-Menopausal Women Initiating Treatment with R | 2020 |
| 2020-12-21 | Biogen, Inc. | $43,997 | Research payment | Cash or cash equivalent | AVONEX Biological, NEUROLOGY | GLB-AVX-19-11478 | 2020 |
| 2020-12-21 | ACADIA Pharmaceuticals Inc | $12,416 | Research payment | Cash or cash equivalent | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | ACP-103-059 | 2020 |
| 2020-12-21 | ABBVIE INC. | $6,666 | Research payment | Cash or cash equivalent | M17-327 | 2020 | |
| 2020-12-21 | Janssen Research & Development, LLC | $3,896 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-12-21 | Travere Therapeutics, Inc. | $1,063 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2020 | |
| 2020-12-21 | GENZYME CORPORATION | $650 | Research payment | Cash or cash equivalent | Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerabi | 2020 | |
| 2020-12-19 | Otsuka Pharmaceutical Co., Ltd. | $1,462 | Research payment | Cash or cash equivalent | PHASE 1-2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF ASTX660 IN SUBJECTS WITH ADVANCED SOLID TUM | 2020 | |
| 2020-12-18 | Janssen Research & Development, LLC | $6,726 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-18 | Bayer Healthcare Pharmaceuticals Inc. | $2,553 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $2,243 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-17 | PFIZER INC. | $9,856 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-12-17 | PFIZER INC. | $6,255 | Research payment | Cash or cash equivalent | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPI | 2020 | |
| 2020-12-17 | Janssen Research & Development, LLC | $5,428 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2020 | |
| 2020-12-17 | Janssen Research & Development, LLC | $3,265 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2020 | |
| 2020-12-17 | Janssen Research & Development, LLC | $2,920 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2020 | |
| 2020-12-17 | Medical Device Business Services, Inc. | $2,600 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-12-17 | Radius Health, Inc. | $2,173 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abalopa | 2020 | |
| 2020-12-17 | Eli Lilly and Company | $1,703 | Research payment | In-kind items and services | RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2020 | |
| 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | $1,320 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE (ASTX727 LD) EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK | 2020 | |
| 2020-12-17 | PFIZER INC. | $1,294 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2020 |
| 2020-12-17 | PFIZER INC. | $1,294 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2020 |
| 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | $1,228 | Research payment | Cash or cash equivalent | PHASE 1-2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF ASTX660 IN SUBJECTS WITH ADVANCED SOLID TUM | 2020 | |
| 2020-12-17 | Abbott Laboratories | $850 | Research payment | Cash or cash equivalent | TactiFlex Ablation Catheter Sensor Enabled Device, Cardiac Arrhythmias and Heart Failure | Safety and Effectiveness of TactiCath Contact Force, Sensor Enabled (TactiCath SE) Catheter for Ablation of Drug Refract | 2020 |
| 2020-12-17 | VYNE Pharmaceuticals Inc. | $722 | Research payment | Cash or cash equivalent | Serlopitant Drug, Pruritus Nodularis | MTI-107 | 2020 |
| 2020-12-17 | ABBVIE INC. | $338 | Research payment | Cash or cash equivalent | M16-109 | 2020 | |
| 2020-12-16 | Corcept Therapeutics | $80,797 | Research payment | Cash or cash equivalent | CORT125134-552 | 2020 | |
| 2020-12-16 | Corcept Therapeutics | $12,383 | Research payment | Cash or cash equivalent | CORT125134-552 | 2020 | |
| 2020-12-16 | Merck Sharp & Dohme LLC | $7,775 | Research payment | Cash or cash equivalent | MK-1454 Drug, ONCOLOGY | Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combinatio | 2020 |
| 2020-12-16 | PFIZER INC. | $4,442 | Research payment | Cash or cash equivalent | JAK1 DUPILUMAB COMPARATOR STUDY | 2020 | |
| 2020-12-16 | Genentech, Inc. | $861 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | TO EVALUATE SAFETY TOLERABILITY AND EFFICACY OF TCB | 2020 |
| 2020-12-16 | Corcept Therapeutics | $390 | Research payment | Cash or cash equivalent | CORT125134-552 | 2020 | |
| 2020-12-16 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $15,413 | Research payment | Cash or cash equivalent | A PHASE 1B STUDY OF TAK-659 IN COMBINATION WITH VENETOCLAX FOR ADULT PATIENTS WITH PREVIOUSLY TREATED NON-HODGKIN LYMPHO | 2020 | |
| 2020-12-15 | PFIZER INC. | $4,205 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-12-15 | Ethicon Endo-Surgery Inc. | $3,152 | Research payment | Cash or cash equivalent | ECHELON FLEX Stapler Device, Endo-Mechanical | An Adaptive, Sequential Evaluation of Powered and Manual Circular Staplers in Left-Sided Colorectal Anastomoses | 2020 |
| 2020-12-15 | PFIZER INC. | $2,288 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-12-15 | ABBVIE INC. | $2,148 | Research payment | Cash or cash equivalent | M15-563 | 2020 | |
| 2020-12-15 | Genentech, Inc. | $800 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE I PROTOCOL COMBO FOR MULTIPLE MYELOMA WITH LENALIDOMIDE | 2020 |
| 2020-12-15 | BioFire Diagnostics, LLC | $100 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | SpotFire STIV Pilot Study | 2020 |
| 2020-12-15 | Ethicon Inc. | $97 | Research payment | Cash or cash equivalent | EVARREST Biological, Biosurgical | A Prospective Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Sealant Patch in Controlling Mild or Mode | 2020 |
| 2020-12-14 | Genentech, Inc. | $62,123 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GENERATION HD1 | 2020 |
| 2020-12-14 | Takeda Pharmaceuticals U.S.A., Inc. | $37,508 | Research payment | Cash or cash equivalent | PHASE 1B/2 STUDY OF TAK-981 IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY CD20-POSITIVE NON-HODGKIN | 2020 | |
| 2020-12-14 | Genentech, Inc. | $8,554 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | TO EVALUATE SAFETY TOLERABILITY AND EFFICACY OF TCB | 2020 |
| 2020-12-14 | Genentech, Inc. | $8,058 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GEN EXTEND | 2020 |
| 2020-12-14 | Merck Sharp & Dohme LLC | $6,670 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II clinical trial of MK-3475 pembrolizumab in subjects with relapsed or refractory R,R classical Hodgkin Lymphom | 2020 |
| 2020-12-14 | Genentech, Inc. | $5,587 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE IB IMMUNO COMBO WITH PDL 1 | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $2,031 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $743 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-12-14 | Alexion Pharmaceuticals, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-12-14 | Merck Sharp & Dohme LLC | $455 | Research payment | Cash or cash equivalent | MK-1454 Drug, ONCOLOGY | Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combinatio | 2020 |
| 2020-12-11 | Genentech, Inc. | $23,190 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | TO EVALUATE SAFETY TOLERABILITY AND EFFICACY OF TCB | 2020 |
| 2020-12-11 | ACADIA Pharmaceuticals Inc | $1,505 | Research payment | Cash or cash equivalent | ACP-2566-004 | 2020 | |
| 2020-12-11 | Genentech, Inc. | $1,337 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | R BENDA CD79B | 2020 |
| 2020-12-11 | Janssen Research & Development, LLC | $600 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-11 | ACADIA Pharmaceuticals Inc | $234 | Research payment | Cash or cash equivalent | ACP-2566-003 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $40 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $40 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $22 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $8 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN1436-4477 | 2020 | |
| 2020-12-10 | CSL Behring | $26,263 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-12-10 | CSL Behring | $3,608 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-12-10 | Genentech, Inc. | $3,118 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | POLARIX | 2020 |
| 2020-12-10 | Incyte Corporation | $2,472 | Research payment | Cash or cash equivalent | A Phase 1-2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosi | 2020 | |
| 2020-12-10 | Abbott Laboratories | $2,300 | Research payment | Cash or cash equivalent | MitraClip Device, Cardiac Arrhythmias and Heart Failure | Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Ca | 2020 |
| 2020-12-10 | Aesculap, Inc. | $557 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Abbott Laboratories | $400 | Research payment | Cash or cash equivalent | MitraClip Device, Cardiac Arrhythmias and Heart Failure | Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Ca | 2020 |
| 2020-12-10 | PFIZER INC. | $264 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2020 | |
| 2020-12-10 | Aesculap, Inc. | $263 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Horizon Therapeutics plc | $153,309 | Research payment | Cash or cash equivalent | KRYSTEXXA Biological, KRYSTEXXA | A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF PEGLOTICASE IN PATIENTS WITH UNCONTROLLED G | 2020 |
| 2020-12-09 | Abbott Laboratories | $20,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Agios Pharmaceuticals, Inc. | $17,812 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinica | 2020 |
| 2020-12-09 | PFIZER INC. | $9,912 | Research payment | Cash or cash equivalent | A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 | 2020 | |
| 2020-12-09 | KLS-Martin L.P. | $8,750 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Abbott Laboratories | $6,895 | Research payment | Cash or cash equivalent | TriClip Transcatheter Tricuspid Valve Repair System Device, Cardiac Arrhythmias and Heart Failure | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2020 |
| 2020-12-09 | KLS-Martin L.P. | $6,250 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | SEAGEN INC. | $4,957 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-09 | KLS-Martin L.P. | $3,750 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | United Therapeutics Corporation | $3,648 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2020 |
| 2020-12-09 | United Therapeutics Corporation | $2,642 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2020 |
| 2020-12-09 | SEAGEN INC. | $493 | Research payment | Cash or cash equivalent | A Study of SGN-CD228A in Advanced Solid Tumors | 2020 | |
| 2020-12-08 | Merck Sharp & Dohme LLC | $12,906 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2020 |
| 2020-12-08 | PFIZER INC. | $2,600 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2020 | |
| 2020-12-08 | Ultragenyx Pharmaceutical Inc. | $2,236 | Research payment | Cash or cash equivalent | Crysvita Drug, XLH Metabolic Bone Disorder | UX023-CL401 | 2020 |
| 2020-12-08 | BioFire Diagnostics, LLC | $1,099 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | SpotFire STIV Pilot Study | 2020 |
| 2020-12-08 | Eli Lilly and Company | $419 | Research payment | In-kind items and services | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODER | 2020 | |
| 2020-12-08 | Incyte Corporation | $195 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal | 2020 | |
| 2020-12-08 | Incyte Corporation | $46 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-12-08 | Incyte Corporation | $46 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-12-08 | Incyte Corporation | $38 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-12-08 | Incyte Corporation | $13 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-12-08 | Incyte Corporation | $4 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-12-07 | Amgen Inc. | $244,963 | Research payment | Cash or cash equivalent | Clinical pathways and outcomes of high-risk HFrEF patients | 2020 | |
| 2020-12-07 | Cook Research Incorporated | $103,650 | Research payment | Cash or cash equivalent | CMH-USARC: US Aortic Research Consortium (GCN 20-86) | 2020 | |
| 2020-12-07 | Amgen Inc. | $74,985 | Research payment | Cash or cash equivalent | Lp(a) and risk for cardiovascular events by race/ethnicity among adults with chronic kidney disease in the Chronic Renal | 2020 | |
| 2020-12-07 | Medical Device Business Services, Inc. | $18,163 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-12-07 | Medical Device Business Services, Inc. | $1,500 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-12-07 | Medical Device Business Services, Inc. | $1,158 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-12-07 | Novo Nordisk AS | $891 | Research payment | In-kind items and services | NN1436-4477 | 2020 |
The latest 200 records of 3,565.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Birmingham, AL, county Jefferson County, AL, state Alabama; placed by its city name.
| Measure | Place (city or town) Birmingham, AL | County Jefferson County, AL | State Alabama |
|---|---|---|---|
| Population B01003 | 198,173 | 667,755 | 5,086,768 |
| Population, 2020 census P1 | 200,733 | 674,721 | 5,024,279 |
| Median age B01002 | 35.6 | 37.7 | 39.3 |
| Under 18 B01001 | 18.9% | 22.9% | 22.2% |
| 65 and over B01001 | 16.4% | 16.8% | 17.8% |
| Households B11001 | 88,788 | 269,883 | 1,997,247 |
| Foreign born B05002 | 4.7% | 4.9% | 4.0% |
| Median household income B19013 | $46,051 | $66,388 | $63,999 |
| Median family income B19113 | $58,445 | $87,393 | $83,032 |
| Per capita income B19301 | $32,216 | $41,013 | $36,087 |
| Poverty rate B17001 | 24.7% | 15.7% | 15.6% |
| Unemployment rate B23025 | 5.8% | 4.7% | 4.7% |
| Civilian labor force B23025 | 97,490 | 326,550 | 2,367,787 |
| Mean commute (minutes) B08013 | 20.8 | 24.1 | 25.5 |
| Bachelor's degree or higher B15003 | 31.1% | 36.2% | 28.4% |
| Housing units B25001 | 109,349 | 310,789 | 2,337,265 |
| Owner-occupied B25003 | 45.5% | 63.9% | 70.2% |
| Renters B25003 | 54.5% | 36.1% | 29.8% |
| Median home value B25077 | $158,800 | $240,000 | $209,900 |
| Median gross rent B25064 | $1,107 | $1,193 | $1,007 |
| White, not Hispanic B03002 | 24.2% | 47.5% | 63.4% |
| Black B03002 | 66.7% | 42.1% | 25.6% |
| Hispanic or Latino B03002 | 4.8% | 5.5% | 5.6% |
| Asian B03002 | 1.4% | 1.9% | 1.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.3% |
Economy now FRED unemployment 3.5% in Sep 2026 (2.8% a year earlier); per capita personal income $59,754 in 2025, up 30% in five years (+4.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Birmingham, AL.
Comments